Answer
Modified-release tablets are licensed for stones associated with low urinary citrate or chronic calcium oxalate stones, recurrent uric acid stones, cystine stones and calcium stones associated with renal tubular acidosis.
Sources for this answer
- Renodyra 1080 mg modified-release tablets — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.